Renol Polychem IPO GMP Price Dates, Financials, and Investment Insights

Renol Polychem Ltd IPO GMP (Renol Polychem IPO) Detail
Renol Polychem Limited is entering the capital markets with its SME IPO to raise ₹25.77 crores. With a promising financial track record, growing sector presence, and a well-defined expansion strategy, investors are showing increasing interest in this IPO. Let’s break down all the essential details, including the latest Renol Polychem IPO GMP updates.

1. Introduction

The Renol Polychem IPO opened for subscription on July 31, 2025, and will close on August 4, 2025. This ₹25.77 crore book-built issue is entirely a fresh issue of 24.54 lakh equity shares, and the company plans to list on the NSE SME platform. The IPO is attracting attention due to its strong growth trajectory and market demand, supported by a promising Renol Polychem IPO GMP in the grey market.

2. About the Company

Renol Polychem Limited, incorporated in 2008 and headquartered in Rajkot, Gujarat, is engaged in the manufacturing of polymer compounds, impact modifiers, and various masterbatches. These are key materials used in the production of PVC, CPVC pipes, plastic furniture, and packaging solutions. The company’s manufacturing facility began commercial operations in 2020 and is equipped with modern machinery.

3. Renol Polychem IPO Details

• IPO Opening Date: July 31, 2025

• IPO Closing Date: August 4, 2025

• Price Band: ₹100 to ₹105 per share

• Lot Size: 1,200 shares

• Issue Size: ₹25.77 crores (entirely fresh issue)

• Listing Platform: NSE SM

• Minimum Retail Investment: ₹2,40,000 (2,400 shares)

• HNI Investment (Min): ₹3,78,000 (3 lots or 3,600 shares)

The investment buzz is amplified by an active Renol Polychem IPO GMP, indicating positive listing expectations.

4. Objects of the IPO

The net proceeds from the IPO will be used for:

• Working capital requirements

• General corporate purposes

• Meeting public issue expenses

These funds will assist Renol Polychem in scaling production and expanding operations.

5. Business Model & Product Portfolio

Renol Polychem’s business model is B2B, catering primarily to pipe manufacturers, packaging industries, and plastic goods producers. Its product categories include:

• Colour Masterbatches

• White & Black Masterbatches

• Filler Granules & Additives

• Impact Modifiers for CPVC/PVC Pipes

With rising demand in construction and agriculture for durable plastic pipes and fittings, Renol is well-positioned.

6. Financial Performance (Last 3 Years)

✅ The company recorded a 19% revenue growth and 27% profit growth in FY24, showcasing operational efficiency and increasing margins.

7. IPO Grey Market Premium (GMP) & Listing Estimate

As of August 2, 2025:

• Renol Polychem IPO GMP Today: ₹18 per share

• Expected Listing Price: ₹123 (₹105 issue price + ₹18 GMP)

💡 The active Renol Polychem IPO GMP in the grey market reflects strong investor confidence and expected listing gains. Tracking GMP helps retail investors estimate post-listing performance and demand strength.

8. Valuation & Peer Comparison

While direct-listed peers are limited in the SME segment, based on FY24 earnings:

• EPS: ₹7.76

• P/E Ratio (at upper band ₹105): ~13.53x

• Industry P/E: ~20–22x (for plastic & chemical manufacturing)

The IPO appears fairly priced compared to its earnings and industry benchmarks. Combined with a healthy Renol Polychem IPO GMP, it makes the offer more appealing.

9. Strengths of the Company

• Diversified product portfolio

• Consistent revenue and profit growth

• Cost-efficient production model

• Growing client base across India

• Experienced management team

10. Weaknesses / Risk Factors

• Dependent on the PVC/CPVC industry cycles

• Operates in a competitive market

• Relatively short operational history (commercial production from 2020)

• SME listing entails liquidity risks

11. IPO Schedule: Date, Allotment & Listing

12. Lot Size & Investment Limits

13. IPO Reservation for Retail, QIB & HNI

As per SME norms:

• Retail Investors: 50% of the issue

• Non-Institutional Investors (HNI): 50%

• No separate reservation for QIBs

14. Promoters & Shareholding Pattern

Promoters:

• Mr. Kishanbhai Savaliya

• Mr. Rajnikant Savaliya